Mode
Text Size
Log in / Sign up
N/A N=23

A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Systemic Fungal Infections

Enrolled (actual)
23
Serious AEs
21.7%
Results posted
Aug 2010
Primary outcome: Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
voriconazole (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Pfizer
Primary completion
Dec 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Diagnosis of Systemic Fungal Infection (SFI)
20; 6; 18; 3; 5; 2
PRIMARY
Management of SFI: Choice of Treatment
12; 11; 3; 3; 2; 1
PRIMARY
Management of SFI: Reason for Selection of Antifungal Agent
PRIMARY
Total Daily Dose for Selected Antifungal Agent
PRIMARY
Number of Participants With Clinical Outcomes.
2; 11; 6; 4
PRIMARY
Number of Participants With Mycological Outcomes
3; 8; 11; 1
SECONDARY
Concomitant Medications
1; 3; 2; 1; 1; 1
SECONDARY
Median Duration of Antifungal Therapy
12.0; 13.0
SECONDARY
Medication Administration
17; 11; 5; 6

Summary

To collect and summarize information on the diagnosis, management, and clinical and mycological outcomes of patients with systemic fungal infections in order to better understand the effectiveness of antifungals in the treatment of Systemic Fungal Infections (SFI) in India.

Eligibility Criteria

Inclusion Criteria

  • To be eligible for enrollment in the study database, patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection.

Exclusion Criteria

  • None.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00721578). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search